Attached files
| file | filename |
|---|---|
| EX-31.2 - EX-31.2 - Frequency Therapeutics, Inc. | freq-ex312_22.htm |
| EX-32.2 - EX-32.2 - Frequency Therapeutics, Inc. | freq-ex322_14.htm |
| EX-32.1 - EX-32.1 - Frequency Therapeutics, Inc. | freq-ex321_8.htm |
| EX-31.1 - EX-31.1 - Frequency Therapeutics, Inc. | freq-ex311_16.htm |
| EX-21.1 - EX-21.1 - Frequency Therapeutics, Inc. | freq-ex211_19.htm |
| EX-10.16 - EX-10.16 - Frequency Therapeutics, Inc. | freq-ex1016_1057.htm |
| 10-K - 10-K - Frequency Therapeutics, Inc. | freq-10k_20201231.htm |
Exhibit 23.1
Consent of Independent Registered Public Accounting Firm
We consent to the incorporation by reference in the Registration Statements (No. 333-233652 and 333-248474) on Form S-1 and Form S-3 (No. 333-250099) of Frequency Therapeutics, Inc. of our report dated March 29, 2021, relating to the consolidated financial statements of Frequency Therapeutics, Inc. and Subsidiaries, appearing in this Annual Report on Form 10-K of Frequency Therapeutics, Inc. for the year ended December 31, 2020.
/s/ RSM US LLP
Boston, Massachusetts
March 29, 2021